Health care stocks were edging up late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.1%.
The iShares Biotechnology ETF (IBB) shed 0.9%.
In corporate news, Bicycle Therapeutics (BCYC) shares plunged past 31% after it said topline data from a phase 1/2 trial of zelenectide pevedotin plus Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.
Candel Therapeutics (CADL) shares sank 30.6% in recent trading, a day after it priced a public offering of 10 million shares at $6 apiece and pre-funded warrants for about 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.
Walgreens Boots Alliance's (WBA) potential buyer Sycamore Partners contacted banks including Bank of America (BAC), JPMorgan (JPM) and Wells Fargo (WFC) to finance a deal of over $10 billion, Sky News reported. Walgreens shares popped 6.8%.
Centene (CNC) stock is undervalued, now that the company has laid out building blocks on how to operate if enhanced affordable care act, or ACA, exchange subsidies expire after 2025, UBS said. UBS upgraded Centene to buy from neutral. Centene shares rose nearly 3%.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。